Wellness Pet Company Announces Financing to Support Strategic Initiatives

Support from existing lending partners enables Wellness Pet to capitalize on growth opportunities Wellness Pet Company (“Wellness Pet” or the “Company”), a leader in pet nutrition for over 25 years, today announced the successful completion of a refinancing transaction, supported by substantial majorities of its existing lenders (the “Transaction”). As part of this transaction, Wellness […]

Lost Money on West Pharmaceutical Services, Inc. (WST)? Contact Levi & Korsinsky Before July 7, 2025 to Join Class Action

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=151069&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Grupo Aeroportuario del Pacifico Announces Drawdown of Ps. 3,375 Million Credit Facility

(NYSE:PAC),(BMV:GAPB.MX), GUADALAJARA, Mexico, May 30, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacifico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces that today it drew down a credit facility with Banco Nacional de Mexico, S.A. (“Banamex”) for Ps. 3,375 million, with a five-year term. Interest will be payable monthly at a

Celularity Receives Nasdaq Notice Regarding Form 10-Q

(NASDAQ:CELU),(NASDAQ:CELUW), FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Notice Regarding Form 10-Q GlobeNewswire May 30, 2025 FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on

Grupo Aeroportuario del Pacifico Announces Drawdown of Ps. 3,375 Million Credit Facility

Grupo Aeroportuario del Pacifico Announces Drawdown of Ps. 3,375 Million Credit Facility GlobeNewswire May 30, 2025 GUADALAJARA, Mexico, May 30, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacifico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces that today it drew down a credit facility with Banco Nacional de Mexico, S.A. (“Banamex”)

Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation – TEM

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. So What: If you purchased Tempus AI securities you may be

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

(NYSE MKT:CATX), Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented [212Pb]VMT-α-NET continued to have a favorable safety profile, with

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting GlobeNewswire May 30, 2025 Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional

IBTA DEADLINE: ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Ibotta, Inc. Investors With Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm – IBTA

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / WHY: New York, N.Y., May 30, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE:IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with

Scroll to Top